An interventional study of Structured patient-centered follow up of depression in Depression, sponsored by Göteborg University. Completed at 1 site in Sweden. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-08-16.
Sponsored by Göteborg University · Not applicable, Interventional, and Health services research
Most people in Sweden with mild to moderate depression are treated in primary care, but follow-up is unstructured, and we know little about whether structured, follow-up would affect the prognosis for depression and working life. The purpose of this study is to determine the effectiveness of regular, structured, patient-centered visits on mild to moderate depression.
8,240 studies on the registry are indexed under Depression; 1,641 are open to participants now.
This study's enrollment of 258 is above the median of 84 across 6,869 interventional studies indexed under Depression.
Browse Depression studies →Göteborg University is the lead sponsor of 270 studies on the registry; 47 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
Participants in the intervention group visit their general practitioner at baseline and 4, 8, and 12 weeks. At each visit, participants complete MADRS-s for the assessment of depression severity and discuss the results with their GP in a patient-centered consultation.
Behavioral: Structured patient-centered follow up of depression
The control group receives treatment as usual by general practitioner (no intervention).
Behavioral: Structured patient-centered follow up of depression
All patients who agree to participate in the study are diagnosed by their GP with a diagnostic assessment instrument called PRIME-MD. Participants in the intervention group visit their GPs at baseline and 4, 8, and 12 weeks. At each visit, participants complete MADRS-s for the assessment of depression severity and discuss the results with their GP in a patient-centered consultation. We have chosen to use the MADRS/MADRS-S depression rating scale in this study because it is a easy to use standard instrument especially suitable for measuring change in depressive symptoms. The control group receives treatment as usual (no intervention).
Also known as: MADRS/MADRS-S depression rating scale
Change in Depressive symptoms
Depressive symptoms will be assessed using the Beck Depression Inventory (BDI-II), a self-administered questionnaire that measures the symptoms and severity of the depression.
Time frame: 3, 6 and 12 months.
Change in Quality of life
Each patient's quality of life will be assessed using the EuroQoL-5D questionnaire that measures five dimensions of quality of life
Time frame: 3, 6 and 12 months
Prescriptions for antidepressants
Information on Antidepressant use will be collected from patient records from start of the study and the 12-month follow-up period
Time frame: 12-month follow-up period
Change in Activity/work ability
Will be measured by Work Ability Index (WAI) and the Karaseks Job Strain Model Questionnaire. The Work Ability Index is used for evaluating people's work capacity and Karaseks Job Strain Model Questionnaire is used for evaluating Demands-Control in work place
Time frame: 12-month follow-up period
sick-listing data
Data on sick-listing is derived from primary care record fom baseline to 3 months follow up and from patient interview from 3 to 12 months
Time frame: 12 month follow up
This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.